First GLP-1 Weight-Loss Pill Approved in China

Managing obesity no longer requires regular injections. For millions of people across the globe, a pill could offer a more convenient option. And now China has taken a major step in that direction. U.S. pharmaceutical giant Eli Lilly has become the first company to receive approval for GLP-1 for weight loss pill in China. The company has beaten its biggest rival, Novo Nordisk, with this milestone.

Until now, GLP-1 medications approved for weight management in China were available only as injections. The Chinese regulator approved Eli Lilly’s oral weight loss drug orforglipron on November 12, 2026. The Danish pharmaceutical company Novo Nordisk is still waiting for the approval of its oral version of Wegovy in China. But with Novo Nordisk also preparing to enter the oral weight loss drug market, the competition has just begun.  

What Is Eli Lilly’s New GLP-1 Weight-Loss Pill?

Eli Lilly’s newly approved drug, orforglipron, is sold under the brand name Foundayo in the United States. This drug belongs to the GLP-1 receptor agonists class of medicines.  The medicines of this class work by mimicking the hormones that are naturally produced in the gut. They help control appetite and regulate blood sugar levels.

This approval marks an important step towards providing patients in China with an oral alternative to injectable GLP-1 weight-loss treatments. However, the pill is not yet confirmed to be commercially available. Eli Lilly is working towards launching orforglipron in China and plans to distribute it through authorised healthcare and pharmaceutical institutions.

Eli Lilly has said that it is working towards launching the medicine commercially in China. The company plans to make the drug available through authorised healthcare and pharmaceutical institutions.

However, the company has not yet revealed its pricing plans for the Chinese market.

Eli Lilly vs Novo Nordisk

Although Eli Lilly has received approval first, Novo Nordisk is not far behind. In August 2026, Chinese regulators accepted Novo Nordisk’s application for its weight-loss pill, oral Wegovy. The pill contains a drug called semaglutide.

Novo Nordisk already has a strong position in the US oral obesity drug market. According to September data shared by the company, oral treatments account for approximately one-third of obesity prescriptions in the United States. Novo Nordisk also accounts for more than 80% of new prescriptions for weight-loss pills.

Clinical trial results have shown differences between the two medicines. Oral Wegovy helped people lose around 14% of their body weight in 64 weeks. Meanwhile, Eli Lilly’s Foundayo showed around 11% weight loss over 72 weeks. 

However, these results come from separate clinical trials and cannot be considered a direct comparison of the two drugs. Sydbank analyst Soren Lontoft Hansen believes Novo Nordisk’s pill could eventually do better than Eli Lilly’s in China. This is because Novo Nordisk’s pill has shown greater weight loss in clinical studies. 

For now, Novo Nordisk has not announced when its pill might receive approval in China.

China’s Weight-Loss Drug Market Could Reach $4.5 Billion 

Obesity is becoming a major healthcare concern in China. According to China’s National Health Commission, the proportion of people who are overweight or obese could exceed 65% by 2030, compared with approximately 50% in 2020. 

This growing concern is also creating opportunities for pharmaceutical companies developing obesity treatments. Yang Huang, head of China healthcare research at J.P. Morgan, expects the country’s GLP-1 weight-loss drug market to grow rapidly. Annual sales could reach 30 billion yuan (around $4.5 billion) in the next five to seven years. 

Currently, annual sales are estimated at 3-4 billion yuan. However, Eli Lilly and Novo Nordisk are not the only companies targeting this market.

Chinese companies are also working on GLP-1 weight-loss pills. These include Jiangsu Hengrui Pharmaceuticals and Huadong Medicine. Industry analysts expect generic versions of semaglutide to enter the Chinese market as early as 2027, potentially increasing competition and driving down weight-loss drug prices.

Why Does This Approval Matter?

For Eli Lilly, receiving approval for its GLP-1 weight-loss pill is an important achievement. However, getting regulatory clearance and becoming the market leader are two different things.

Eli Lilly will now be focusing on launching the pill in China and making it available to patients. Novo Nordisk is also planning to enter the market with its oral Wegovy. 

Obesity rates are rising in China, and more pharmaceutical companies are developing weight-loss medicines. This is expected to increase competition in China’s GLP-1 drug market.

Eli Lilly is the first to enter China’s oral weight-loss drug market. However, it is still too early to say which company will become the market leader.